Experimental pill aims to ease thick heart muscle symptoms

NCT ID NCT07675668

Not yet recruiting Disease control Sponsor: Amckaus PTY LTD. Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This phase 2 trial tests an oral drug called Aom0304 in adults with hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The study includes people with both obstructive and non-obstructive forms. Participants receive different doses of Aom0304 for 12 weeks to find the safest and most effective dose, with dose adjustments every two weeks. The goal is to see if the drug can improve symptoms and heart function without serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aom0304 (enteric coated capsule)
What this could lead to: If successful, this could point toward a new oral treatment option for hypertrophic cardiomyopathy, potentially improving exercise capacity and reducing heart blockage.
What could go wrong: This is an early-phase trial with only 56 participants, so results may not apply to all patients. The drug may cause side effects like reduced heart function or abnormal lab results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC CARDIOMYOPATHY (HCM) NON-OBSTRUCTIVE HCM (NHCM) OBSTRUCTIVE HCM (OHCM)

More trials for these conditions

Other studies related to the condition(s) this trial covers.